Soleno Therapeutics Announces Updates to its Board of Directors
Soleno Therapeutics (NASDAQ: SLNO) announced changes to its Board of Directors. Dawn Carter Bir, a seasoned biotech executive with over 30 years of industry experience, has been appointed to the Board. Ernest Mario, Ph.D. is stepping down as Chair due to health reasons, and Matthew Pauls, J.D., M.B.A. is assuming the role of Lead Independent Director.
Ms. Bir's extensive experience in commercialization, strategic business development, and global operational leadership is expected to be valuable as Soleno prepares for a potential launch of DCCR. She recently served as Executive VP and Chief Commercial Officer at Reata Pharmaceuticals, contributing to the company's first product approval and launch, leading to a $7.3B acquisition by Biogen in 2023.
Soleno Therapeutics (NASDAQ: SLNO) ha annunciato modifiche al suo Consiglio di Amministrazione. Dawn Carter Bir, un esperto nel settore biotech con oltre 30 anni di esperienza, è stata nominata nel Consiglio. Ernest Mario, Ph.D. si dimette dalla carica di Presidente per motivi di salute e Matthew Pauls, J.D., M.B.A. assumerà il ruolo di Direttore Indipendente Principale.
La vasta esperienza della signora Bir nella commercializzazione, nello sviluppo strategico del business e nella leadership operativa globale sarà preziosa mentre Soleno si prepara a un'eventuale lancio del DCCR. Recentemente ha ricoperto il ruolo di VP Esecutivo e Direttore Commerciale presso Reata Pharmaceuticals, contribuendo all'approvazione e al lancio del primo prodotto dell'azienda, che ha portato a un'acquisizione di $7,3 miliardi da parte di Biogen nel 2023.
Soleno Therapeutics (NASDAQ: SLNO) anunció cambios en su Junta Directiva. Dawn Carter Bir, una ejecutiva del sector biotecnológico con más de 30 años de experiencia en la industria, ha sido nombrada para la Junta. Ernest Mario, Ph.D. dejará su cargo como Presidente por razones de salud, y Matthew Pauls, J.D., M.B.A. asumirá el rol de Director Independiente Principal.
Se espera que la amplia experiencia de la Sra. Bir en comercialización, desarrollo estratégico de negocios y liderazgo operativo global sea valiosa mientras Soleno se prepara para un posible lanzamiento de DCCR. Recientemente se desempeñó como Vicepresidenta Ejecutiva y Directora Comercial en Reata Pharmaceuticals, contribuyendo a la aprobación y lanzamiento del primer producto de la empresa, lo que llevó a una adquisición de $7.3 mil millones por parte de Biogen en 2023.
솔레노테라퓨틱스(SNASDAQ: SLNO)가 이사회를 변경한다고 발표했습니다. Dawn Carter Bir는 30년 이상의 바이오텍 산업 경험을 가진 베테랑 경영자입니다. Ernest Mario, Ph.D.는 건강 문제로 회장직에서 물러나고, Matthew Pauls, J.D., M.B.A.가 독립적인 수석 이사 역할을 맡게 됩니다.
Bir 여사의 상업화, 전략적 사업 개발 및 글로벌 운영 리더십에 대한 광범위한 경험은 솔레노가 DCCR의 잠재적 출시를 준비하는 데 있어 매우 귀중할 것으로 예상됩니다. 그녀는 최근 리타 제약의 부사장 겸 최고 상업 책임자로 재직하면서 회사의 첫 제품 승인 및 출시를 이끌어 2023년 바이오젠의 73억 달러 인수에 기여했습니다.
Soleno Therapeutics (NASDAQ: SLNO) a annoncé des changements au sein de son Conseil d'Administration. Dawn Carter Bir, une cadre expérimentée dans le secteur biopharmaceutique avec plus de 30 ans d'expérience, a été nommée au Conseil. Ernest Mario, Ph.D. démissionne de son poste de Président pour des raisons de santé, et Matthew Pauls, J.D., M.B.A. assume le rôle de Directeur Indépendant Principal.
L'expérience considérable de Mme Bir en matière de commercialisation, de développement stratégique des affaires et de leadership opérationnel mondial devrait s'avérer précieuse alors que Soleno se prépare à un lancement potentiel de DCCR. Elle a récemment été Vice-Présidente Exécutive et Directrice Commerciale chez Reata Pharmaceuticals, contribuant à l'approbation et au lancement du premier produit de l'entreprise, conduisant à une acquisition de 7,3 milliards de dollars par Biogen en 2023.
Soleno Therapeutics (NASDAQ: SLNO) hat Änderungen im Aufsichtsrat angekündigt. Dawn Carter Bir, eine erfahrene Führungskraft in der Biotechnologie mit über 30 Jahren Branchenerfahrung, wurde in den Vorstand berufen. Ernest Mario, Ph.D. tritt aus gesundheitlichen Gründen als Vorsitzender zurück, und Matthew Pauls, J.D., M.B.A. übernimmt die Rolle des leitenden unabhängigen Direktors.
Frau Birs umfassende Erfahrung in der Kommerzialisierung, strategischen Geschäftsentwicklung und globaler operative Führung wird als wertvoll angesehen, während Soleno sich auf eine mögliche Einführung des DCCR vorbereitet. Kürzlich war sie als Executive VP und Chief Commercial Officer bei Reata Pharmaceuticals tätig und trug zur Genehmigung und Einführung des ersten Produkts des Unternehmens bei, was 2023 zu einer Übernahme durch Biogen im Wert von 7,3 Milliarden Dollar führte.
- Appointment of Dawn Carter Bir, an experienced biotech executive, to the Board of Directors
- New board member brings extensive commercialization and strategic expertise
- Company is preparing for potential launch of DCCR, indicating progress in product development
- Chairman Ernest Mario stepping down from the Board due to health reasons
Ernest Mario, Ph.D. steps down as Chair for health reasons; Matthew Pauls, J.D., M.B.A. assumes role of Lead Independent Director
Dawn Carter Bir, seasoned biotech executive with significant commercial and strategic expertise, joins the Board of Directors
REDWOOD CITY, Calif., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced updates to its Board of Directors. Dawn Carter Bir, a seasoned biotechnology executive with over 30 years of industry executive leadership and strategic experience, has been appointed to Soleno’s Board of Directors. In addition, Board Chairman Ernest Mario, Ph.D. is stepping down from the Board due to health reasons. Current Board member Matthew Pauls, J.D., M.B.A. is assuming the role of Lead Independent Director.
“We wish Dr. Mario well as he steps down from the Board. We extend our sincere gratitude to him for his invaluable contributions as the Chairman of our Board,” said Anish Bhatnagar, M.D., Chief Executive Officer of Soleno Therapeutics. “His extensive pharmaceutical industry experience, spanning over four decades, has been instrumental in guiding Soleno’s growth towards becoming a commercial stage company.”
“We are also pleased to welcome Ms. Bir to Soleno’s Board of Directors. She has a wealth of experience in commercialization, strategic business development and global operational leadership spanning more than 30 years. Her extensive experience will be instrumental as we prepare for a potential launch of DCCR.”
Ms. Bir said, “I am delighted to be joining Soleno’s Board and work towards advancing the company as DCCR approaches potential approval. I look forward to collaborating with the talented Soleno team to help support its growth as they prepare to potentially commercialize their first product.”
Ms. Bir recently served as Executive Vice President, member of the core executive team, and Chief Commercial Officer of Reata Pharmaceuticals for over seven years through the company’s first product approval and launch and
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company recently submitted an NDA to the FDA, supported by its Phase 3 development program, for its lead candidate, DCCR (diazoxide choline) extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS). For more information, please visit www.soleno.life.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding the timing of any regulatory process and ultimate approvals for DCCR for the treatment of PWS. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including the risks and uncertainties associated with the FDA’s filing and / or review of our NDA, market conditions, as well as risks and uncertainties inherent in Soleno’s business, including those described in the company's prior press releases and in the periodic reports it files with the SEC. The events and circumstances reflected in the company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, the company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
FAQ
Who is the new board member appointed to Soleno Therapeutics (SLNO)?
Why is Ernest Mario stepping down from Soleno Therapeutics' (SLNO) Board?
Who is taking over as Lead Independent Director at Soleno Therapeutics (SLNO)?
What product is Soleno Therapeutics (SLNO) preparing to potentially launch?
